An open-label, phase 2 trial of RPI.4610 in the treatment of metastatic breast cancer
Cancer, 05/07/2012Morrow PK et al.
Most common adverse events (AEs) were: injection site reactions, abdominal pain, anorexia, chromaturia, constipation, dyspnea, fatigue, headache, pain at the injection site, nausea, vomiting, and fever. Although RPI.4610 demonstrated a well–tolerated safety profile, its lack of clinical efficacy precludes this drug from further development.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.